DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Drug: Ipatasertib
Drug: Entinostat
Drug: Fulvestrant
Drug: Bevacizumab
Drug: Exemestane
Drug: Abemaciclib
Drug: Tamoxifen

First Posted Date: 2017-09-12

Last Posted Date: 2024-10-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 138

Registration Number: NCT03280563

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 24 locations

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps

Phase 3

Completed

Conditions: Nasal Polyps
Chronic Rhinosinusitis

Interventions: Drug: Placebo
Drug: Omalizumab

First Posted Date: 2017-09-12

Last Posted Date: 2020-03-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 127

Registration Number: NCT03280537

Locations: 🇪🇸
Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain
🇧🇪
UZ Gent, Gent, Belgium
🇵🇱
Synexus - Warsaw, Warszawa, Poland

and more 42 locations

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine Placebo
Drug: Polatuzumab vedotin Placebo

First Posted Date: 2017-09-07

Last Posted Date: 2025-03-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03274492

Locations: 🇷🇺
Leningrad Regional Clinical Hospital, St Petersburg, Sankt Petersburg, Russian Federation
🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 213 locations

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Phase 3

Terminated

Conditions: Advanced BRAFV600 Wild-type Melanoma

Interventions: Drug: Cobimetinib
Drug: Pembrolizumab
Drug: Atezolizumab

First Posted Date: 2017-09-06

Last Posted Date: 2022-09-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 446

Registration Number: NCT03273153

Locations: 🇺🇸
USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States
🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 118 locations

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib

First Posted Date: 2017-09-05

Last Posted Date: 2022-11-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 355

Registration Number: NCT03271554

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of

and more 33 locations

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Phase 2

Completed

Conditions: Beta-Thalassemia

Interventions: Drug: Bitopertin

First Posted Date: 2017-09-05

Last Posted Date: 2018-10-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT03271541

Locations: 🇮🇹
Ospedale Maggiore di Milano; Cardio-Metabolic Diseases, Milano, Lombardia, Italy
🇹🇭
Siriraj Hospital; Division of Haematology-Oncology, Bangkok Noi, Thailand
🇱🇧
Chronic Care Center, Baabda, Lebanon

and more 1 locations

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Phase 2

Completed

Conditions: Solid Tumors

Interventions: Drug: Cobimetinib
Drug: Atezolizumab Cohort 7
Drug: Atezolizumab

First Posted Date: 2017-08-28

Last Posted Date: 2021-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 87

Registration Number: NCT03264066

Locations: 🇧🇪
AZ Groeninge, Kortrijk, Belgium
🇭🇺
Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 16 locations

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

Not Applicable

Completed

Conditions: Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease

Interventions: Other: Spirometry
Other: Accelerometry
Other: 6MWT

First Posted Date: 2017-08-24

Last Posted Date: 2021-03-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 178

Registration Number: NCT03261037

Locations: 🇮🇹
A.O.U. S. Luigi Gonzaga; Interstiziopatie Malattie Rare Polmone, Orbassano (to), Piemonte, Italy
🇫🇷
Hopital Cote De Nacre; Pneumologie, Caen, France
🇫🇷
Hopital de Pontchaillou; Service de Pneumologie, Rennes, France

and more 34 locations

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Phase 1

Completed

Conditions: Diffuse Large B-cell Lymphoma
High-Grade B-cell Lymphoma

Interventions: Drug: RO6870810
Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2017-08-21

Last Posted Date: 2022-01-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 39

Registration Number: NCT03255096

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇦🇺
Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia

and more 6 locations

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Gantenerumab

First Posted Date: 2017-08-02

Last Posted Date: 2018-12-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 114

Registration Number: NCT03236844

Locations: 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
🇺🇸
PRA, Marlton, New Jersey, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy